Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8N118
UPID:
CP4X1_HUMAN
Alternative names:
CYPIVX1
Alternative UPACC:
Q8N118; G3V1U1; Q5VVE5; Q6ZN67; Q8NAZ3
Background:
Cytochrome P450 4X1, alternatively known as CYPIVX1, plays a crucial role in the metabolism of endocannabinoids, particularly through the epoxidation of anandamide's arachidonoyl moiety. This enzyme, a cytochrome P450 monooxygenase, is unique in its selective catalytic activity, which does not extend to fatty acids, steroids, or prostaglandins. It operates by inserting one oxygen atom into its substrate and reducing the second oxygen atom into water, utilizing electrons supplied by NADPH via cytochrome P450 reductase.
Therapeutic significance:
Understanding the role of Cytochrome P450 4X1 could open doors to potential therapeutic strategies, especially in modulating endocannabinoid signaling, which is pivotal in various physiological processes.